India, June 26 -- Plus Therapeutics, Inc. (PSTV), a clinical-stage pharmaceutical company, expects the revenue contributions of CNSide Diagnostics, LLC to "become meaningful" in fiscal year 2026.
The proprietary CNSide Cerebrospinal Fluid (CSF) Assay Platform is designed and intended for patients suspected of having central nervous system cancer metastases (CNS Mets). The first test to be commercialized, CNSide CSF Tumor Cell Enumeration (TCE), has a total addressable market estimated to be $6 billion in the U.S.
Andrew Sims, Plus Therapeutics' Vice President and Chief Financial Officer. "We anticipate that while CNSide's launch is on track for 2025, given our current forecasts the revenue contributions of the CNSide subsidiary will becom...